Welcome to the UPF Digital Repository

Nationwide COVID-19-EII study: incidence, environmental risk factors and long-term follow-up of patients with inflammatory bowel disease and COVID-19 of the ENEIDA registry

Show simple item record

dc.contributor.author Zabana, Yamile
dc.contributor.author López, Alicia
dc.contributor.author The Eneida Registry Of Geteccu
dc.date.accessioned 2022-09-30T05:51:11Z
dc.date.available 2022-09-30T05:51:11Z
dc.date.issued 2022
dc.identifier.citation Zabana Y, Marín-Jiménez I, Rodríguez-Lago I, Vera I, Martín-Arranz MD, Guerra I et al. Nationwide COVID-19-EII study: incidence, environmental risk factors and long-term follow-up of patients with inflammatory bowel disease and COVID-19 of the ENEIDA registry. J Clin Med. 2022 Jan 14;11(2):421. DOI: 10.3390/jcm11020421
dc.identifier.issn 2077-0383
dc.identifier.uri http://hdl.handle.net/10230/54229
dc.description.abstract We aim to describe the incidence and source of contagion of COVID-19 in patients with IBD, as well as the risk factors for a severe course and long-term sequelae. This is a prospective observational study of IBD and COVID-19 included in the ENEIDA registry (53,682 from 73 centres) between March-July 2020 followed-up for 12 months. Results were compared with data of the general population (National Centre of Epidemiology and Catalonia). A total of 482 patients with COVID-19 were identified. Twenty-eight percent were infected in the work environment, and 48% were infected by intrafamilial transmission, despite having good adherence to lockdown. Thirty-five percent required hospitalization, 7.9% had severe COVID-19 and 3.7% died. Similar data were reported in the general population (hospitalisation 19.5%, ICU 2.1% and mortality 4.6%). Factors related to death and severe COVID-19 were being aged ≥ 60 years (OR 7.1, 95% CI: 1.8-27 and 4.5, 95% CI: 1.3-15.9), while having ≥2 comorbidities increased mortality (OR 3.9, 95% CI: 1.3-11.6). None of the drugs for IBD were related to severe COVID-19. Immunosuppression was definitively stopped in 1% of patients at 12 months. The prognosis of COVID-19 in IBD, even in immunosuppressed patients, is similar to that in the general population. Thus, there is no need for more strict protection measures in IBD.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartof J Clin Med. 2022 Jan 14;11(2):421
dc.rights © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
dc.rights.uri https://creativecommons.org/licenses/by/4.0/
dc.title Nationwide COVID-19-EII study: incidence, environmental risk factors and long-term follow-up of patients with inflammatory bowel disease and COVID-19 of the ENEIDA registry
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/jcm11020421
dc.subject.keyword COVID-19
dc.subject.keyword SARS-CoV-2
dc.subject.keyword Inflammatory bowel disease
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking